Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
63
BMED Quote, Financials, Valuation and Earnings
Last price:
$30.84
Seasonality move
:
-4.16%
Day range:
$30.68 - $30.88
52-week range:
$20.57 - $30.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
1.1K
Avg. volume:
3.1K
1-year change:
20.84%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BMED
iShares Health Innovation Active ETF
|
-- | -- | -- | -- | -- |
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BMED
iShares Health Innovation Active ETF
|
$30.71 | -- | -- | -- | $0.01 | 0% | -- |
|
CANC
Tema Oncology ETF
|
$35.41 | -- | -- | -- | $0.02 | 0.06% | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
$36.36 | -- | -- | -- | $0.00 | 0% | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
$58.33 | -- | -- | -- | $0.51 | 0.88% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BMED
iShares Health Innovation Active ETF
|
-- | 0.918 | -- | -- |
|
CANC
Tema Oncology ETF
|
-- | 0.905 | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | 1.197 | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | 0.523 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BMED
iShares Health Innovation Active ETF
|
-- | -- | -- | -- | -- | -- |
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- | -- |
iShares Health Innovation Active ETF vs. Competitors
-
Which has Higher Returns BMED or CANC?
Tema Oncology ETF has a net margin of -- compared to iShares Health Innovation Active ETF's net margin of --. iShares Health Innovation Active ETF's return on equity of -- beat Tema Oncology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BMEDiShares Health Innovation Active ETF-- -- -- CANCTema Oncology ETF-- -- -- -
What do Analysts Say About BMED or CANC?
iShares Health Innovation Active ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Tema Oncology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Health Innovation Active ETF has higher upside potential than Tema Oncology ETF, analysts believe iShares Health Innovation Active ETF is more attractive than Tema Oncology ETF.
Company Buy Ratings Hold Ratings Sell Ratings BMEDiShares Health Innovation Active ETF0 0 0 CANCTema Oncology ETF0 0 0 -
Is BMED or CANC More Risky?
iShares Health Innovation Active ETF has a beta of 0.901, which suggesting that the stock is 9.904% less volatile than S&P 500. In comparison Tema Oncology ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BMED or CANC?
iShares Health Innovation Active ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0%. Tema Oncology ETF offers a yield of 0.06% to investors and pays a quarterly dividend of $0.02 per share. iShares Health Innovation Active ETF pays -- of its earnings as a dividend. Tema Oncology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BMED or CANC?
iShares Health Innovation Active ETF quarterly revenues are --, which are smaller than Tema Oncology ETF quarterly revenues of --. iShares Health Innovation Active ETF's net income of -- is lower than Tema Oncology ETF's net income of --. Notably, iShares Health Innovation Active ETF's price-to-earnings ratio is -- while Tema Oncology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Health Innovation Active ETF is -- versus -- for Tema Oncology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMEDiShares Health Innovation Active ETF-- -- -- -- CANCTema Oncology ETF-- -- -- --
-
Which has Higher Returns BMED or HTEC?
ROBO Global Healthcare Technology & Innovation ETF has a net margin of -- compared to iShares Health Innovation Active ETF's net margin of --. iShares Health Innovation Active ETF's return on equity of -- beat ROBO Global Healthcare Technology & Innovation ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BMEDiShares Health Innovation Active ETF-- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -
What do Analysts Say About BMED or HTEC?
iShares Health Innovation Active ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ROBO Global Healthcare Technology & Innovation ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Health Innovation Active ETF has higher upside potential than ROBO Global Healthcare Technology & Innovation ETF, analysts believe iShares Health Innovation Active ETF is more attractive than ROBO Global Healthcare Technology & Innovation ETF.
Company Buy Ratings Hold Ratings Sell Ratings BMEDiShares Health Innovation Active ETF0 0 0 HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 -
Is BMED or HTEC More Risky?
iShares Health Innovation Active ETF has a beta of 0.901, which suggesting that the stock is 9.904% less volatile than S&P 500. In comparison ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.215, suggesting its more volatile than the S&P 500 by 21.472%.
-
Which is a Better Dividend Stock BMED or HTEC?
iShares Health Innovation Active ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0%. ROBO Global Healthcare Technology & Innovation ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iShares Health Innovation Active ETF pays -- of its earnings as a dividend. ROBO Global Healthcare Technology & Innovation ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BMED or HTEC?
iShares Health Innovation Active ETF quarterly revenues are --, which are smaller than ROBO Global Healthcare Technology & Innovation ETF quarterly revenues of --. iShares Health Innovation Active ETF's net income of -- is lower than ROBO Global Healthcare Technology & Innovation ETF's net income of --. Notably, iShares Health Innovation Active ETF's price-to-earnings ratio is -- while ROBO Global Healthcare Technology & Innovation ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Health Innovation Active ETF is -- versus -- for ROBO Global Healthcare Technology & Innovation ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMEDiShares Health Innovation Active ETF-- -- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- --
-
Which has Higher Returns BMED or JDOC?
JPMorgan Healthcare Leaders ETF has a net margin of -- compared to iShares Health Innovation Active ETF's net margin of --. iShares Health Innovation Active ETF's return on equity of -- beat JPMorgan Healthcare Leaders ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BMEDiShares Health Innovation Active ETF-- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- -
What do Analysts Say About BMED or JDOC?
iShares Health Innovation Active ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand JPMorgan Healthcare Leaders ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Health Innovation Active ETF has higher upside potential than JPMorgan Healthcare Leaders ETF, analysts believe iShares Health Innovation Active ETF is more attractive than JPMorgan Healthcare Leaders ETF.
Company Buy Ratings Hold Ratings Sell Ratings BMEDiShares Health Innovation Active ETF0 0 0 JDOCJPMorgan Healthcare Leaders ETF0 0 0 -
Is BMED or JDOC More Risky?
iShares Health Innovation Active ETF has a beta of 0.901, which suggesting that the stock is 9.904% less volatile than S&P 500. In comparison JPMorgan Healthcare Leaders ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BMED or JDOC?
iShares Health Innovation Active ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0%. JPMorgan Healthcare Leaders ETF offers a yield of 0.88% to investors and pays a quarterly dividend of $0.51 per share. iShares Health Innovation Active ETF pays -- of its earnings as a dividend. JPMorgan Healthcare Leaders ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BMED or JDOC?
iShares Health Innovation Active ETF quarterly revenues are --, which are smaller than JPMorgan Healthcare Leaders ETF quarterly revenues of --. iShares Health Innovation Active ETF's net income of -- is lower than JPMorgan Healthcare Leaders ETF's net income of --. Notably, iShares Health Innovation Active ETF's price-to-earnings ratio is -- while JPMorgan Healthcare Leaders ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Health Innovation Active ETF is -- versus -- for JPMorgan Healthcare Leaders ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMEDiShares Health Innovation Active ETF-- -- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
